Founded in 2020, Barinthus Biotherapeutics plc (BRNS) is a biopharmaceutical company with the ambitious goal of revolutionising treatment for those suffering from significant high unmet diseases on a global scale. Leveraging a unique and potent blend of scientific expertise and entrepreneurial drive, BRNS is built on a foundation of innovative and ground-breaking research.
Barinthus Biotherapeutics' fundamental mission centres on the development and ultimate commercialization of innovative biopharmaceuticals for the treatment of serious diseases. Core areas of therapeutic concentration have historically been within the orphan diseases, neurology, immunology, and ophthalmology space.
Utilizing cutting-edge technological advancements to propel the creation and development of novel drugs, BRNS fosters a powerfully diverse and robust pipeline rich with potential. It's a testament to their commitment to dramatically improve the quality of life for patients living with debilitating, and oftentimes rare, diseases.
At the helm of Barinthus Biotherapeutics is a seasoned, interdisciplinary leadership team. Comprised of life sciences veterans, the group brings a collective track record of proven success in drug discovery, clinical development, regulatory approval and the commercial launch of groundbreaking therapies. Employees worldwide are committed to this cause, driven by shared values of innovation, excellence, and integrity.
Through strategic collaborations and partnerships, BRNS expands its global reach and enhances the potential impact of its therapeutic solutions. By leveraging partners' strengths, Barinthus Biotherapeutics can expedite drug development timelines and deliver lifesaving therapies to patients who need them faster.
BRNS takes pride in a culture of innovation and believes that its strength lies in its people. With respect for diversity and inclusion as well as an emphasis on professional growth, BRNS has nurtured an environment of discovery and collaboration.
Known for its commitment to the betterment of humanity, Barinthus Biotherapeutics also carries a specific ethos of corporate social responsibility. The company takes environmental considerations seriously and consciously works to minimize the carbon footprint of its operations.
As it continues to grow and push boundaries, Barinthus Biotherapeutics remains fully committed to its mission: to develop innovative, life-changing therapies that offer hope and solutions to patients living with high burden diseases. Standing at the cutting edge of drug discovery and development, the future for BRNS looks both exciting and promising.